Objective: To evaluate the efficacy and safety of vigabatrin in pediatric epilepsy. Methods: We retrospectively reviewed patients with epilepsy treated with vigabatrin over a 2-year period at a pediatric tertiary center. We assessed the relationship between seizure frequency, etiology, vigabatrin dose, adverse events, medication discontinuation reasons, and electroencephalography (EEG) characteristics. Results: One hundred three patients followed at Boston Children's Hospital were treated with vigabatrin and had complete medical records. Within the follow-up interval, 69 (67%) of 103 patients had discontinued vigabatrin therapy. Two patients (1.9%) died during therapy for unknown reasons. Median age at vigabatrin initiation was 8 months (interquartile range [IQR] 5-15). Median starting dose was 48.1 mg/kg per day (IQR 29.8-52.3) with a median target of 100 mg/kg (IQR 81.9-107.9). Median treatment duration was 12.1 months (n = 89, IQR 5.0-22.9) overall, and 13.3 months (IQR 5.2-23.2) for patients who discontinued vigabatrin. The most common reasons for discontinuation were controlled seizures in 31 (43.7%) of 71 and unsatisfactory therapeutic effect in 23 (32.4%) of 71. Median percent seizure reduction from baseline to first follow-up was 83.3% (IQR 27.4-99.8) and 96.7% (IQR 43.3-100) to last follow-up. Twentyfour (38.7%) of 62 patients with a follow-up posttreatment remained seizure-free. Four patients who had initially achieved seizure freedom relapsed. Patients with structural/ metabolic etiology had greater median percent seizure reduction at first follow-up than patients with genetic etiology (98.7% vs. 61.4%, respectively, p = 0.001). Hypsarrhythmia resolved after therapy in 18 of 20 (90%, 95% confidence interval [CI] 70-97) patients with pretreatment hypsarrhythmia, and 2 patients presented with hypsarrhythmia posttreatment. Risk of having hypsarrhythmia was reduced by 32% (95% CI 14.9-49.1) posttreatment. Significance: Vigabatrin is efficacious in all seizure types and resolved hypsarrhythmia in most patients. In this series with a median treatment duration of 12.1 months, vigabatrin had a good safety profile with a low rate of discontinuation due to nonophthalmologic and ophthalmologic adverse effects.
therapy in adult patients with complex partial seizures. 6 Several studies have reported efficacy of vigabatrin in partial seizures with [7] [8] [9] [10] [11] and without 8, 10 tuberous sclerosis complex (TSC) etiology in the pediatric population. There is controversy with regard to efficacy of vigabatrin compared to adrenocorticotropic hormone (ACTH) and oral corticosteroids in infantile spasms in terms of seizure control and retention, as well as long-term cognitive outcome. 2, 4, 5, [12] [13] [14] [15] The literature reports varying responder rates for short-term vigabatrin therapy of 3-6 months in a variety of refractory epilepsies, 11, [16] [17] [18] whereas the longterm effect on seizure control and the safety profile in patients with refractory epilepsy and multiple seizure types has yet to be determined.
The most serious adverse effects of vigabatrin are the irreversible concentric bilateral visual field deficits, reported in approximately 28.6% of patients with ages 8-12 years. Specifics of vigabatrin administration in pediatrics beyond infantile spasms and TSC etiology are lacking in the literature, as are details on the subset of children who do well on vigabatrin therapy. 19 Many studies do not comprehensively evaluate treatment long-term, and reports of side effects are limited regarding magnetic resonance imaging (MRI) and visual field effects. 20 Currently, physicians must evaluate the risk of developing a peripheral visual field defect or MRI abnormality. 21, 22 There are not many postmarket approval studies for vigabatrin therapy outside of its current U.S. Food and Drug Administration (FDA)-approved use.
We aimed to evaluate the efficacy and safety profile of vigabatrin beyond its current FDA approval, encompassing all pediatric ages and a variety of refractory epilepsies, seizure types, and etiologies.
Methods

Patient selection
Approval from Boston Children's Hospital Institutional Review Board was obtained prior to data acquisition. We retrospectively reviewed all consecutive electronic medical records of patients diagnosed with epilepsy who were treated with vigabatrin at Boston Children's Hospital, a pediatric tertiary center over a 2-year period. Medical records that did not document the vigabatrin initiation date and/or baseline seizure frequency prior to initiation and/or seizure frequency at follow-up were excluded.
Data collection
Data were extracted from clinical descriptions in the medical records and collected in REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN, U.S.A.), a secure web-based application that facilitates data acquisition and storage. We evaluated demographic data, clinical characteristics, and details regarding seizure characterization and frequency at baseline and during vigabatrin treatment.
Epilepsy and etiology classification and seizure control
Epileptic seizures and etiology were classified according to International League Against Epilepsy (ILAE) criteria. 23 TSC was characterized as a structural/metabolic etiology. Seizure frequency was calculated as the average number of seizures over a 30-day period. Responders were defined as patients who had a ≥50% reduction in seizure frequency compared to baseline seizure frequency prior to starting vigabatrin therapy. Responder rate and seizure frequency were analyzed at the first and last follow-up. Seizure frequency data were extracted systematically and interpreted from the medical records. Subjective terms and descriptions of the number of seizures or seizure frequency were assigned a numerical value to maintain consistency of data collection. Five patients who underwent epilepsy surgery and one patient diagnosed with infantile spasms who did not have clinical seizures prior to medication initiation, during and following vigabatrin treatment were excluded from seizure reduction or seizure cessation calculations. Patients who underwent epilepsy surgery while on treatment were not excluded from the study because they provide insight into the demographics of this series; however, they were excluded from the seizure frequency analysis due to the potential confounding effect of epilepsy surgery.
Ninety-nine patients were included in the seizure frequency analysis at first follow-up and 88 patients were included in the seizure frequency analysis at last follow-up. Four patients were excluded from the first follow-up seizure frequency analysis due to epilepsy surgery in one; no follow-up appointments while on vigabatrin treatment in two; and no observed clinical seizures prior, during, and postvigabatrin therapy in one (the patient's infantile spasms were clinically controlled by clonazepam and ACTH prior to starting vigabatrin; however, they were not controlled electrographically). Fifteen patients were excluded from the last follow-up seizure frequency analysis due to no followup appointment while on vigabatrin treatment in nine patients; epilepsy surgery while on treatment in five; and no observed clinical seizures prior, during, and post-vigabatrin therapy in one patient.
Vigabatrin dosing
We analyzed the relationship between vigabatrin dosing and seizure reduction at first and last follow-up and the relationship between vigabatrin dosing and occurrence of adverse effects. Low and high doses were dichotomized at the median of the first follow-up. 
Statistical analysis
Results
Patient identification
Two hundred ninety-six electronic patient medical records were screened. Of these patients, 69 were not treated with vigabatrin and 124 had incomplete medical data. The remaining 103 patients were included in the study. At the completion of data acquisition, 69 (67%) of the 103 patients had discontinued vigabatrin therapy, 2 (1.9%) expired during therapy due to unknown reasons, and the remaining 32 (31.1%) continued treatment.
Demographics
Demographic data and clinical characteristics are presented in Table 1 . Two patients expired during therapy. One patient was 12.2 years old, had Aicardi syndrome, and was clinically declining, whereas the other patient was 3.2 months old, had malformation of cortical development, and expired during sleep. The medical records did not provide further information or autopsy results for either patient.
Seizure type
At initial presentation, 71 (68.9%) patients had one seizure type, 26 (25.2%) had two, 5 (4.9%) had three, and one (0.97%) had four seizure types. Upon vigabatrin initiation, 80 (77.7%) patients had one seizure type, 15 (14.6%) had two seizure types, and 8 (7.8%) had three (Table 1) .
Antiepileptic medications and treatments
Prior to vigabatrin therapy, 34 patients (33%) were not treated with any antiepileptic drug (AED) and 69 (67%) were treated with concomitant Of five patients who underwent epilepsy surgery during vigabatrin therapy, four had hemispherectomies. Three of these patients had malformation of cortical development and one had a stroke. The remaining patient had TSC and underwent a temporal lobectomy.
Vigabatrin titration schedule and dose
The median dose at first follow-up was 100 mg/kg per day (IQR 79. and at last follow-up was 93.8 mg/kg per day (IQR 54-128.6). There was no correlation between dose and seizure reduction at first or last follow-up (Spearman's rho correlation, p = 0.075 and 0.371, respectively). Dichotomized at the first follow-up median dose, there was no correlation between low and high dose and seizure reduction at first or last follow-up (Mann-Whitney U test, p = 0.077 and p = 0.183, respectively).
Overall seizure control
Seizure frequency reduction of ≥50% was observed in 72 (72.7%) of 99 patients at the first follow-up, with 24 (24.2%) reaching complete seizure freedom and in 64 (72.7%) of 88 patients at last follow-up, with 33 (37.5%) reaching complete seizure freedom (Fig. 1) . No difference regarding etiology was observed in responder rate at first or last follow-up (v 2 test, p = 0.172 and p = 0.919, respectively).
Seizure frequency reduction from baseline to first followup was 83.3% (n = 99, IQR 27.4-99.8) and from baseline to last follow-up was 96.7% (n = 88, IQR 43.3-100). There was no difference between the effect of short-and long-term therapy on seizure control (Wilcoxon signed-rank test, p = 0.448, Fig. S1 ).
Patients who had a shorter delay to treatment from their initial seizure presentation had a greater percent seizure reduction as demonstrated by the negative correlation between treatment delay and percent seizure reduction at last follow-up (Spearman's correlation coefficient = À0.408, p < 0.001). Patients who started vigabatrin treatment at a younger age had a greater percent seizure reduction at last follow-up (Spearman's correlation coefficient = À0.307, p = 0.004).
Seizure type and seizure frequency
Seizure frequency stratified by seizure type at first and last follow-up with and without epileptic spams is presented in Table 2 . Patients who had only focal seizures exhibited a 94.9% seizure reduction (n = 3, IQR À612.5 to 94.9) at first follow-up, whereas two patients who exhibited only generalized tonic-clonic seizures had a 100% (IQR 100-100) seizure reduction at first follow-up (Table 2) .
Etiology and seizure frequency
Etiology, seizure type, and seizure frequency characteristics at first follow-up are presented in Table 2 . For all analyses, patients with TSC were considered as having a structural/metabolic etiology. Patients with structural/metabolic etiology had a greater seizure frequency reduction at first follow-up, with a 98.7% (n = 49, IQR 63.9-100) seizure reduction, than patients with a genetic etiology, with 61.4% (n = 23, IQR À28.6 to 85.2) seizure reduction (Mann-Whitney U test, Z = À3.341, p = 0.001). Patients with a structural/metabolic etiology had a higher seizure reduction than patients with an unknown etiology, with 74.3% (n = 27, IQR À9.1 to 98.3) seizure reduction at first follow-up (Mann-Whitney U test, p = 0.056, Fig. S2 ).
Furthermore, patients diagnosed with TSC had a higher percent seizure reduction (100%, n = 25, IQR 82.5-100) as compared to patients with a genetic etiology (61.4%, n = 23, IQR À28.6 to 85.2, Mann-Whitney U test, Z = À3.626, p < 0.001, Fig. 2 ). Patients with a malformation of cortical development had an 88.2% (IQR 67.9-99.5) seizure frequency reduction at first follow-up. No additional differences were observed between etiologies in seizure reduction.
Seizure freedom
Sixty-two of the 71 patients who discontinued vigabatrin had a follow-up appointment after vigabatrin withdrawal, excluding five who had undergone epilepsy surgery. Twenty-eight (42.5%) of these 62 patients reached complete seizure freedom during treatment. Twenty-four (24/62, 38.7%) remained seizure-free after withdrawal of vigabatrin, whereas four (4/62, 6.5%) relapsed following treatment withdrawal.
Five patients who did not reach seizure freedom on vigabatrin therapy were seizure-free after therapy. Reasons for withdrawing from vigabatrin included the following: adverse effects in three, unsatisfactory therapeutic effect in one, and unspecified reasons in one patient.
Of the five patients who had epilepsy surgery while on vigabatrin, three reached complete seizure freedom following surgery and remained seizure-free following vigabatrin withdrawal, with the discontinuation reason of controlled seizures in two and adverse effects in one patient. The remaining two patients did not reach seizure freedom on vigabatrin therapy, but were seizure-free following withdrawal. These two patients had withdrawn from treatment due to controlled seizures in one and unspecified reasons in the other.
Electroencephalography (EEG) results
Electroencephalography (EEG) activity normalized in 7 of 49 (14.3%, 95% confidence interval [CI] 26.6-71) patients following vigabatrin therapy, which included 3 patients with genetic etiology, one patient with structural/ metabolic etiology, and 3 patients with unknown etiology. However, abnormal activity appeared in one patient with a previously normal EEG recording. Risk of abnormal EEG was not different posttreatment compared to pretreatment (n = 50 with EEG reports both before and after treatment, risk difference = À12%, 95% CI À24.6 to À5.8, p = 0.07). EEG activity normalized in 7 of 78 (9%, 95% CI 4.4-17.4) patients during treatment and included three patients with structural/metabolic etiology and four patients with unknown etiology.
Hypsarrhythmia was observed in 38% of patients prior to treatment (n = 38/100 with an EEG), in 17.1% during treatment (n = 14/82 with an EEG), and in 7.5% after treatment termination (n = 4/53 with an EEG). Hypsarrhythmia resolved after therapy completion in 18 of 20 (90%, 95% CI 70-97) who had hypsarrhythmia prior to starting treatment, and included 4 patients with genetic etiology, 8 patients with structural/metabolic etiology, and 6 patients with unknown etiology. Of 30 patients without hypsarrhythmia prior to treatment, 2 patients presented with hypsarrhythmia posttreatment. Risk of having hypsarrhythmia was reduced by 32% posttreatment (95% CI 14.9-49.1, n = 50 with an EEG pretreatment and posttreatment, McNemar's test, p = 0.004).
In addition, hypsarrhythmia resolved during treatment in 23 of 31 (74.2%, 95% CI 56.8-86.3%) patients with hypsarrhythmia prior to treatment and included 5 patients with genetic etiology, 8 patients with structural/metabolic etiology, and 10 patients with unknown etiology. Of 48 patients without hypsarrhythmia prior to treatment, six presented with hypsarrhythmia during treatment (risk difference during the treatment compared to pretreatment: À21.5% (95% CI À7.76 to À35.3%, n = 79 with an EEG before and during treatment, McNemar's test, p = 0.002). There was no difference in the proportion of patients that presented with hypsarrhythmia during and after vigabatrin therapy. Of 17 patients with hypsarrhythmia pretreatment and a follow-up visit with available EEG posttreatment, 7 (41.2%, 95% CI 21.6-64.0) had both seizure freedom and resolution of hypsarrhythmia at last follow-up.
MRI results
Of 11 patients without abnormalities on MRI prior to vigabatrin therapy, 7 presented with an abnormality while on or during therapy on their MRI exam. Of 45 patients who had displayed abnormalities on MRI prior to therapy, only one had a normal MRI exam while on or during therapy (n = 56 with MRI exams both prior to and while/post therapy, McNemar's test, p = 0.07).
Adverse effects
Fifteen adverse effects were observed in 14 (19.7%) of 71 patients who discontinued vigabatrin. The most common adverse events were vision abnormalities in six patients (8.5%), including electroretinography (ERG) changes from baseline in five (7%) and abnormal visual tracking in one (1.4%) patient. An increase in seizures was observed in three patients (4.2%), tiredness/fatigue in two (2.8%), and the following were each observed in one (1.4%) patient: anemia, possible vigabatrin-related toxicity, medication toxicity, and anorexia (Fig. 3) .
There was no correlation between dosage and an occurrence of adverse events at the first follow-up. However, there was a correlation between dosage and an occurrence of adverse events at last follow-up, as patients who had an adverse event were treated with 133.9 mg/kg per day (IQR 73.6-173.7) and those without adverse events were on 87.4 mg/kg per day (IQR 50.5-121.6) (n = 88, Mann-Whitney U test, Z = À2.176, p = 0.03, Fig. S3 ).
Discontinuation reasons
Of 103 patients, 71 (68.9%) discontinued vigabatrin therapy, whereas 32 (31.1%) continued treatment at last follow-up. The most common reasons for discontinuation were controlled seizures in 31 (43.7%) of 71, unsatisfactory therapeutic effect in 23 (32.4%) of 71, and adverse effects in 9 patients (12.6%), including 5 (7%) who stopped therapy due to ophthalmologic abnormalities seen on the ERG exam. Abnormalities in both the B-wave stimulus/response function and low amplitude in response to the 30 Hz flickering white stimuli were observed in four patients, whereas one patient had only B-wave response abnormalities. Other less common reasons for Epilepsia ILAE withdrawal were unknown in six patients (8.5%) and controlled hypsarrhythmia in one patient (1.4%). Two patients (2.8%) expired for unspecified reasons (Fig. 3) . There was no significant difference in the duration of treatment among discontinuation reason (log-rank test, p = 0.313).
Eye exam results
Patients underwent a variety of ophthalmologic evaluations before, during, and after treatment including general visual acuity, confrontation, kinetic and static perimetry, ERG, optical coherence tomography, preferential looking test, visually evoked potentials, retinoscopy, and ophthalmoscopy.
Ophthalmologic exam results prior to vigabatrin therapy were available for 49 (47.6%) of 103 patients. Fifteen (30.6%) of the 49 patients exhibited no abnormalities, whereas the remaining 34 (69.4%) exhibited 36 abnormalities due to TSC, an underlying disease, refractive errors, medication, and unknown reasons. Some patients exhibited more than one abnormality.
Ophthalmologic exam results during vigabatrin therapy were available for 92 (89.3%) of 103 patients. Thirty-six patients had exhibited a normal eye exam at least once during treatment. Sixty-two patients had at least one ERG exam during treatment: 54 patients had one ERG exam, whereas eight had two ERG exams during the course of treatment. We observed that 80.6% (50/62) of patients with an ERG during treatment had shown abnormalities on an ERG exam. Evaluating one ERG exam per patient, 31 (50%) of 62 patients exhibited abnormalities in the scotopic B-wave sensitivity response, 18 (29%) of 62 exhibited both abnormalities in the B-wave response and amplitude of the response to 30 Hz flickering light, and one patient (1.6%) exhibited an abnormality in the amplitude of the 30 Hz flickering light response.
Ophthalmologic exam results regarding post-vigabatrin therapy were available for 49 (47.6%) of 103 patients. Eighteen patients (36.7%) exhibited no abnormalities, whereas the remaining 31 patients (63.3%) exhibited 35 abnormalities due to TSC, an underlying disease, refractive errors, and unknown reasons. Six patients had an ERG exam following treatment. Three patients exhibited abnormalities in the scotopic B-wave sensitivity response and two exhibited both abnormalities in the B-wave response and amplitude of the 30 Hz flickering light response.
Discussion
Summary
Our retrospective study on the safety and efficacy of vigabatrin in 103 children at a tertiary pediatric center revealed a high responder rate, with 72.7% of patients having ≥50% seizure frequency reduction with both short-and long-term therapy. Vigabatrin treatment among children with a variety of seizure types and etiologies not only ameliorated seizure outcomes, but was well tolerated, with a low discontinuation rate due to adverse events (12.6%) and seizure exacerbation (32.4%), and a low relapse rate (6.5%) postvigabatrin therapy, and it also resolved hypsarrhythmia with satisfactory success.
Study population
Our study focused on patients younger than 11 years of age with a variety of etiologies and seizure types treated with vigabatrin monotherapy and/or adjunctive therapy, including a large proportion of refractory cases. Table S1 and Text S1 review the most recent prospective and Adverse effects and discontinuation reason in patients that discontinued therapy. Of 103 patients, 71 (68.9%) discontinued vigabatrin therapy, whereas 32 (31.1%) continued treatment at the completion of data acquisition. Fifteen adverse effects were observed in 14 (19.7%) of 71 patients who discontinued vigabatrin. *One patient discontinued because of controlled seizures and a vision abnormality. Epilepsia ILAE observational studies on vigabatrin therapy for epilepsy and seizure disorders in the pediatric population. Many studies that encompass multiple seizure types and etiologies have also included an older pediatric and adult population, 7, 10, 11, [16] [17] [18] [24] [25] [26] whereas our series is concentrated solely on younger children, of which many have previously failed to respond to multiple medications.
Short-term seizure outcome
Vigabatrin was effective at improving seizure outcome in children as short-term therapy. At a median of 1.6 months, seizure frequency had decreased 83.3% from baseline, and 72.7% of patients had ≥50% seizure reduction on a dosage of 100 mg/kg/day. Concordant with our findings, similar retrospective studies in a variety of seizure types including infantile spasms observed that 70.2% of patients had >50% seizure reduction within 1-5 months, 10 whereas another study reported a responder rate of 67.2% at 3 months. 11 Epileptic spasms were prevalent in 91.3% of our series, and 24.2% were seizure-free at 1.6 months. Our results are in accordance with previously reported findings of seizure cessation in 30.3% with a variety of seizure types including infantile spasms within 1-5 months. 10 Long-term seizure outcome Improved seizure outcome was maintained for a median of 12.1 months, with 96.7% seizure frequency reduction and 72.7% of patients with ≥50% seizure reduction. This is similar to the literature reporting responder rates of 68.7%, 27 75.9%, 28 and 80% 29 in infantile spasms; 76.3% in new-onset partial seizures 30 ; and 88.5% in partial and generalized epilepsies at 6 months. 31 Seizure freedom was observed in 37.5% at 12.1 months, leading to continued seizure cessation in 38.7% following vigabatrin withdrawal. Our results are further corroborated by studies reporting 32.8% seizure freedom at 6 months in multiple seizure types including infantile spasms 8 and 36.8% spasms cessation. 15 
Relapse
Our rate of posttreatment relapse was 6.5% and is generally lower than indicated in the current literature. Analogous to our study, the literature on infantile spasms reports relapse rates of 6% at 6 months 32 and 6.3% at 12 months, 14 as well as higher rates of 11.1% at 19.2 months 33 and 19.8% after 28 days of spasm freedom. 3 Previous findings also report a higher relapse rate of 23.7% in new-onset partial seizures 30 and 31.3% in seizures at 12 months.
14 Age and timing to treatment Our results suggest that patients who start vigabatrin treatment at an earlier age may have a better seizure outcome. This finding is corroborated by a previous finding that demonstrated higher response rates and seizure freedom before 2 years with an even greater response before 6 months. 10 Furthermore, a shorter delay to treatment from seizure onset may improve seizure outcome. Our findings were further strengthened by a study comparing early vigabatrin treatment within 1 week of seizure onset with those treated 3 weeks or later from seizure onset which revealed that patients treated very early after seizure onset were more likely to be seizure-free and have a better cognitive outcome. 34 This is further substantiated by the United Kingdom Infantile Spasms Study trial 35 that demonstrated that early treatment may ameliorate seizure outcome in infantile spasms and improve the cognitive outcome and by a report that children with a shorter delay between onset and treatment, and a longer time on vigabatrin, had a better cognitive effect. 36 Duration of seizures of <12 months was also seen to improve seizure outcome. 10 
Etiology
Corroborated by previous reports, seizure outcome was better in patients with a structural/metabolic etiology, in particular, TSC. Response rates in patients with TSC etiology ranged from 21.1% to 86% in previous studies. 10, 11, [36] [37] [38] 
Hypsarrhythmia
Hypsarrhythmia resolved post-vigabatrin treatment in 90% of the patients with an EEG pre-and posttreatment and in 74.2% with an EEG pre-and during treatment. There is much variability in the literature, ranging from 8.3% to 100% elimination of hypsarrhythmia. In accordance with our findings, hypsarrhythmia resolution was reported in 71.4%, 39 78.6%, 13 and 80% of patients. 29 
Safety
Our study revealed adverse effects in 19.7% of patients. The most common were vision abnormalities observed in 8.5%, an increase in seizures in 4.2%, and tiredness/fatigue in 2.8%. Our findings are consistent with those of others who observed adverse effects in 18% (visual field defects in 3.6% and drowsiness in 1.8%), 17 in 21.9% (seizure exacerbation in 6.8% and visual field defects in 16.6%), 25 in 22.2% (somnolence in 11.1%), 33 and in 22.9% (ERG changes in 2%) (Text S2). 40 
Vigabatrin discontinuation
Our discontinuation rate of 68.9% is also in accordance with previous findings ranging from 50.7% to 57.1%. 18, 25, 26 We observed that 7% discontinued vigabatrin treatment due to ophthalmologic abnormalities, a finding consistent with a reported rate of 7.7% 31 (Table S2 and Text S2).
Dosage
Our study did not observe a linear dose response or difference in the effect of a lower or higher dosage on seizure outcome. However, patients treated with a higher dosage did exhibit more adverse events despite the comparable seizure outcome between the lowerand higher-dosage patients. Previous studies have observed no differences between high and low dosages dichotomized at the median 26 or a dose response in a variety of seizure types. 16 
Challenges
Results need to be interpreted in the setting of retrospective data acquisition. Based on our approach, it was not possible to report seizure frequency according to seizure type because medical records did not consistently document seizure frequency for each seizure type. Seizure frequency data were extracted systematically and interpreted from electronic medical records. In a small number of cases, qualitative assessments of seizure frequency were reported in the medical records. To prevent exclusion bias and avoid excluding the valuable data from these patients, the qualitative and colloquial terms describing seizure frequency were defined quantitatively. Because of our retrospective approach, we were unable to compare patients to a control group and not all patients underwent all clinical examinations. The study was conducted at a tertiary pediatric center, and thus patient selection may be biased toward patients who have intractable epilepsy and may be difficult to treat. Patients were treated with multiple medications and treatments to achieve seizure control and as a result, treatment outcomes and adverse effects cannot solely be attributed to a single treatment.
Conclusions
Our study suggests that vigabatrin provides good seizure control as both short-and long-term therapy among patients who were refractory to previous medications with a variety of seizure types and etiologies. Vigabatrin was observed to resolve hypsarrhythmia with good success and was well-tolerated during the treatment period of 12.1 months, with limited potential risks and a low rate of discontinuation due to adverse effects (12.6%).
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